Pearson plc is leveraging AI-driven efficiency and digital transformation to drive sustained margin expansion and free cash flow growth. Learn more about PSO stock here.

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies, which assessed the efficacy and safety of ICOTYDE™ ...

Mar 28, 2026-- Takeda ( TSE:4502/NYSE:TAK ) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279 ...

Two Phase 3 clinical studies evaluated the efficacy and safety of zasocitinib in patients with moderate to severe plaque psoriasis and found promising results. Approximately 70% of ...

The benchmark KSE-100 Index closed at 148,743.32 points, registering a gain of 1,900.34 points or 1.29%.

71.4% and 69.2% of patients treated with zasocitinib achieved a static Physician Global Assessment (sPGA) score of 0/1 versus placebo (10.7% and 12.6%) and apremilast (32.1% and 29.7%) at week 16 (p<0 ...

One month after a decision was made to discontinue Skybus flights from Newquay to London, a major airline has announced it will now be offering a new connection to the capital ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults furt ...

Ryanair's chief executive, Michael O'Leary, has cautioned about "the risk of supply disruptions in Europe in May and June" ...

Following a 5% increase in KSE-30 Index a market halt was triggered. “Due to a 5% Increase in the KSE-30 index from the ...